Loomis, Sayles & Company
LXRX icon

Loomis, Sayles & Company’s Lexicon Pharmaceuticals LXRX Stock Holding History

Loomis, Sayles & Company’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-986,386
Closed -$12.1M – 901
2017
Q3 		$12.1M Buy
986,386
+103,037
+12% +$1.52M 0.03% 380
2017
Q2 		$14.5M Sell
883,349
-30,484
-3% -$472K 0.03% 329
2017
Q1 		$13.1M Buy
913,833
+75,461
+9% +$1.12M 0.03% 360
2016
Q4 		$11.6M Sell
838,372
-43,077
-5% -$691K 0.03% 401
2016
Q3 		$15.9M Sell
881,449
-192,755
-18% -$3.1M 0.04% 326
2016
Q2 		$15.4M Sell
1,074,204
-33,191
-3% -$450K 0.04% 337
2016
Q1 		$13.2M Sell
1,107,395
-3,002
-0.3% -$31.5K 0.04% 377
2015
Q4 		$14.8M Buy
+1,110,397
New +$13.7M 0.04% 358

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Loomis, Sayles & Company's LXRX Position: Q4 2017 in Review

Loomis, Sayles & Company sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 986,386 shares — an estimated $12.1M sold.

Loomis, Sayles & Company first reported a position in LXRX in Q4 2015 and held it in 8 quarters. The position peaked at $15.9M in Q3 2016. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Loomis, Sayles & Company reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 986,386 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $12.1M.
  • Loomis, Sayles & Company first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Loomis, Sayles & Company's Lexicon Pharmaceuticals position peaked at $15.9M in Q3 2016.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Loomis, Sayles & Company's 13F filing for Q4 2017, filed 14 Feb 2018.